Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00357968 · ClinicalTrials.gov registry record · Phase 2
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
NCT00357968 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 201 participants.
The verdict
NCT00357968, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
Study Summary
The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary intervention (PCI).
Interventions
- DRUG Clopidogrel
- DRUG Prasugrel
- DRUG Placebo for Prasugrel
- DRUG Placebo for Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00357968
The ClinicalTrials.gov registry entry for NCT00357968 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Clopidogrel is the first listed.
NCT00357968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00357968 about?
NCT00357968 is a clinical study titled "Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting". The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary intervention (PCI).
What is the current status of trial NCT00357968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2006-08. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00357968?
The interventions under investigation include: Clopidogrel (DRUG), Prasugrel (DRUG), Placebo for Prasugrel (DRUG), Placebo for Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT00357968?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.